Teplizumab Biosimilar - Research Grade

Human

CD3E

>1mg/ml

Human IgG1 (L234A/L235A/E356D/M358L)-Kappa

Bulk Anti-Human CD3 (UCHT-1) Antibody (ICH1002), Anti-CD3e (500A2) In Vivo Antibody - Low Endotoxin (ICH1040), Anti-CD3e (145-2C11) In Vivo Antibody - Low Endotoxin (ICH1041), Bulk Anti-Human CD3 (OKT-3) Antibody (ICH1257), Muromonab Biosimilar - Research Grade (ICH5024), Mosunetuzumab Biosimilar - Research Grade (ICH5026), Foralumab Biosimilar - Research Grade (ICH5156), Otelixizumab Biosimilar - Research Grade (ICH5171), Dafsolimab Biosimilar - Research Grade (ICH5460), Emirodatamab Biosimilar - Research Grade (ICH5520), Visilizumab Biosimilar - Research Grade (ICH5982)

https://www.imgt.org/mAb-DB/

ICH3002

P07766

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of teplizumab, an anti-CD3 monoclonal antibody engineered to engage the CD3 epsilon chain of the T-cell receptor (TCR) complex. It is built around the same target specificity as the originator drug and is supplied strictly for research use only (RUO); it is not the clinical drug and is not intended for human or veterinary use. The molecule is expressed as a human IgG1 carrying Fc-region substitutions (here L234A/L235A, which reduce Fcgamma-receptor engagement and effector function) so that binding can be studied largely independent of ADCC/CDC. It is useful as a well-defined positive control and reference reagent for CD3 epsilon binding and TCR-modulation assays, for benchmarking anti-CD3 candidates, for T-cell activation and internalization studies, and as an isotype/effector-function comparator. Available at bulk milligram-to-gram scale with low-endotoxin grades (research grade less than 1 EU/mg; ultra-low less than 0.5 EU/mg) suitable for endotoxin-sensitive in-vitro and preclinical work. No clone identity is implied. CD3 epsilon (CD3E, UniProt P07766) is an invariant subunit of the CD3 signaling module of the T-cell receptor (TCR) complex. It pairs with CD3 gamma and CD3 delta and associates with the disulfide-linked CD3 zeta homodimer and the antigen-binding TCR alpha/beta heterodimer to form the mature TCR-CD3 complex on T lymphocytes. CD3 epsilon contributes an extracellular immunoglobulin-like domain and a cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM); upon TCR engagement, Lck-mediated ITAM phosphorylation recruits ZAP-70 and triggers downstream signaling that drives T-cell activation, proliferation, and differentiation. Because CD3 epsilon is essential for surface assembly and signal transduction of the TCR, it is a central node for modulating T-cell responses. Anti-CD3 epsilon antibodies can modulate or internalize the TCR complex and influence T-cell activation and tolerance.

CD3E, IMD18, T3E, TCRE, CD3e molecule, CD3epsilon, CD3 epsilon subunit of T-cell receptor complex

Detects human CD3E

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

LALA

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Teplizumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Teplizumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Teplizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Teplizumab that binds human CD3E.